HuGE Literature Finder
Records
1
-
7
| Phase 1b dose expansion and translational analyses of olaparib in combination with capivasertib in recurrent endometrial, triple negative breast, and ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2021 Sep . Westin Shannon N, Labrie Marilyne, Litton Jennifer K, Blucher Aurora, Fang Yong, Vellano Christopher P, Marszalek Joseph R, Feng Ningping, Ma Xiaoyan, Creason Allison, Fellman Bryan, Yuan Ying, Lee Sanghoon, Kim TaeBeom, Liu Jinsong, Chelariu-Raicu Anca, Chen Tsun Hsuan, Kabil Nashwa, Soliman Pamela T, Frumovitz Michael, Schmeler Kathleen M, Jazaeri Amir, Lu Karen H, Murthy Rashmi, Meyer Larissa, Sun Charlotte, Sood Anil K, Coleman Robert L, Mills Gordon |
| Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. The Lancet. Oncology 2016 Sep . Ledermann Jonathan A, Harter Philipp, Gourley Charlie, Friedlander Michael, Vergote Ignace, Rustin Gordon, Scott Clare, Meier Werner, Shapira-Frommer Ronnie, Safra Tamar, Matei Daniela, Fielding Anitra, Spencer Stuart, Rowe Philip, Lowe Elizabeth, Hodgson Darren, Sovak Mika A, Matulonis Ursu |
| A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. Gynecologic oncology 2015 Jun 137 (3): 386-91. Coleman Robert L, Sill Michael W, Bell-McGuinn Katherine, Aghajanian Carol, Gray Heidi J, Tewari Krishnansu S, Rubin Steven C, Rutherford Thomas J, Chan John K, Chen Alice, Swisher Elizabeth |
| The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. The Lancet. Oncology 2013 Aug 14 (9): 882-92. Sandhu Shahneen K, Schelman William R, Wilding George, Moreno Victor, Baird Richard D, Miranda Susana, Hylands Lucy, Riisnaes Ruth, Forster Martin, Omlin Aurelius, Kreischer Nathan, Thway Khin, Gevensleben Heidrun, Sun Linda, Loughney John, Chatterjee Manash, Toniatti Carlo, Carpenter Christopher L, Iannone Robert, Kaye Stan B, de Bono Johann S, Wenham Robert |
| The influence of BRCA1/BRCA2 mutations on toxicity related to chemotherapy and radiotherapy in early breast cancer patients. Oncology 2013 85 (5): 278-82. Huszno Joanna, Budryk Magdalena, Ko?osza Zofia, Nowara El?bie |
| Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. The Lancet. Oncology 2011 Sep 12 (9): 852-61. Gelmon Karen A, Tischkowitz Marc, Mackay Helen, Swenerton Kenneth, Robidoux André, Tonkin Katia, Hirte Hal, Huntsman David, Clemons Mark, Gilks Blake, Yerushalmi Rinat, Macpherson Euan, Carmichael James, Oza Am |
| Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet (London, England) 2010 Jul 376 (9737): 235-44. Tutt Andrew, Robson Mark, Garber Judy E, Domchek Susan M, Audeh M William, Weitzel Jeffrey N, Friedlander Michael, Arun Banu, Loman Niklas, Schmutzler Rita K, Wardley Andrew, Mitchell Gillian, Earl Helena, Wickens Mark, Carmichael Jam |
- Page last reviewed:Jul 25, 2022
- Page last updated:Aug 10, 2022
- Content source: